Dopaminergic Midbrain Neurons Are the Prime Target for Mitochondrial DNA Deletions

Overview

Journal J Neurol

Specialty Neurology

Date 2008 Jul 8

PMID 18604467

Citations 46

Authors

Andreas Bender

Rachel-Maria Schwarzkopf

Anja McMillan

Kim J Krishnan

Gabriele Rieder

Manuela Neumann

Matthias Elstner

Douglas M Turnbull

Thomas Klopstock

Affiliations

Soon will be listed here.

Abstract

Mitochondrial dysfunction is a consistent finding in neurodegenerative disorders like Alzheimer's (AD) or Parkinson's disease (PD) but also in normal human brain aging. In addition to respiratory chain defects, damage to mitochondrial DNA (mtDNA) has been repeatedly reported in brains from AD and PD patients. Most studies though failed to detect biologically significant point mutation or deletion levels in brain homogenate. By employing quantitative single cell techniques, we were recently able to show significantly high levels of mtDNA deletions in dopaminergic substantia nigra (SN) neurons from PD patients and age-matched controls. In the present study we used the same approach to quantify the levels of mtDNA deletions in single cells from three different brain regions (putamen, frontal cortex, SN) of patients with AD (n = 9) as compared to age-matched controls (n = 8). There were no significant differences between patients and controls in either region but in both groups the deletion load was markedly higher in dopaminergic SN neurons than in putamen or frontal cortex (p < 0.01; ANOVA). This data shows that there is a specific susceptibility of dopaminergic SN neurons to accumulate substantial amounts of mtDNA deletions, regardless of the underlying clinical phenotype.

Citing Articles

Dopaminergic neuron metabolism: relevance for understanding Parkinson's disease.

Flores-Ponce X, Velasco I Metabolomics. 2024; 20(6):116.

PMID: 39397188 PMC: 11471710. DOI: 10.1007/s11306-024-02181-4.

A genome on shaky ground: exploring the impact of mitochondrial DNA integrity on Parkinson's disease by highlighting the use of cybrid models.

Lang M, Grunewald A, Pramstaller P, Hicks A, Pichler I Cell Mol Life Sci. 2022; 79(5):283.

PMID: 35513611 PMC: 9072496. DOI: 10.1007/s00018-022-04304-3.

Alcohol-Induced Neuroinflammatory Response and Mitochondrial Dysfunction on Aging and Alzheimer's Disease.

Leon B, Kang S, Franca-Solomon G, Shang P, Choi D Front Behav Neurosci. 2022; 15:778456.

PMID: 35221939 PMC: 8866940. DOI: 10.3389/fnbeh.2021.778456.

Comprehensive summary of mitochondrial DNA alterations in the postmortem human brain: A systematic review.

Valiente-Palleja A, Tortajada J, Bulduk B, Vilella E, Garrabou G, Muntane G EBioMedicine. 2022; 76:103815.

PMID: 35085849 PMC: 8790490. DOI: 10.1016/j.ebiom.2022.103815.

Region-specific vulnerability in neurodegeneration: lessons from normal ageing.

Pandya V, Patani R Ageing Res Rev. 2021; 67:101311.

PMID: 33639280 PMC: 8024744. DOI: 10.1016/j.arr.2021.101311.

References

Anandatheerthavarada H, Biswas G, Robin M, Avadhani N . Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol. 2003; 161(1):41-54. PMC: 2172865. DOI: 10.1083/jcb.200207030. View

Fukui H, Diaz F, Garcia S, Moraes C . Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2007; 104(35):14163-8. PMC: 1955773. DOI: 10.1073/pnas.0705738104. View

Krishnan K, Bender A, Taylor R, Turnbull D . A multiplex real-time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. Anal Biochem. 2007; 370(1):127-9. DOI: 10.1016/j.ab.2007.06.024. View

Reddy P . Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal. 2007; 9(10):1647-58. DOI: 10.1089/ars.2007.1754. View

Coskun P, Beal M, Wallace D . Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A. 2004; 101(29):10726-31. PMC: 490002. DOI: 10.1073/pnas.0403649101. View

Manczak M, Park B, Jung Y, Reddy P . Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004; 5(2):147-62. DOI: 10.1385/NMM:5:2:147. View

Greene J, Dingledine R, Greenamyre J . Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis. 2005; 18(1):19-31. DOI: 10.1016/j.nbd.2004.10.003. View

Cottrell D, Borthwick G, Johnson M, Ince P, Turnbull D . The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease. Neuropathol Appl Neurobiol. 2002; 28(5):390-6. DOI: 10.1046/j.1365-2990.2002.00414.x. View

Werkman T, Kruse C, Nievelstein H, Long S, Wadman W . In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs. Neuropharmacology. 2001; 40(7):927-36. DOI: 10.1016/s0028-3908(01)00015-6. View

10.

Lin M, Beal M . Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443(7113):787-95. DOI: 10.1038/nature05292. View

11.

Sciacco M, Bonilla E, Schon E, DiMauro S, Moraes C . Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet. 1994; 3(1):13-9. DOI: 10.1093/hmg/3.1.13. View

12.

Betts J, Lightowlers R, Turnbull D . Neuropathological aspects of mitochondrial DNA disease. Neurochem Res. 2004; 29(3):505-11. DOI: 10.1023/b:nere.0000014821.07269.8d. View

13.

Hamblet N, Castora F . Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. Mutat Res. 1997; 379(2):253-62. DOI: 10.1016/s0027-5107(97)00158-9. View

14.

Krishnan K, Greaves L, Reeve A, Turnbull D . The ageing mitochondrial genome. Nucleic Acids Res. 2007; 35(22):7399-405. PMC: 2190723. DOI: 10.1093/nar/gkm635. View

15.

Khan F, Sen T, Maiti A, Jana S, Chatterjee U, Chakrabarti S . Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim Biophys Acta. 2005; 1741(1-2):65-74. DOI: 10.1016/j.bbadis.2005.03.013. View

16.

Gluck M, Ehrhart J, Jayatilleke E, Zeevalk G . Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J Neurochem. 2002; 82(1):66-74. DOI: 10.1046/j.1471-4159.2002.00938.x. View

17.

Bender A, Krishnan K, Morris C, Taylor G, Reeve A, Perry R . High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006; 38(5):515-7. DOI: 10.1038/ng1769. View

18.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

19.

Atamna H, Frey 2nd W . Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion. 2007; 7(5):297-310. DOI: 10.1016/j.mito.2007.06.001. View

20.

Shamoto-Nagai M, Maruyama W, Yi H, Akao Y, Tribl F, Gerlach M . Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome. J Neural Transm (Vienna). 2005; 113(5):633-44. DOI: 10.1007/s00702-005-0410-5. View